Sci Simple

New Science Research Articles Everyday

# Biology # Biochemistry

Fungal Findings: Nature’s Hidden Antibacterial Agent

A promising fungus shows potential against drug-resistant bacteria.

Ting He, Xiao Li, Rosario del Carmen Flores-Vallejo, Ana-Maria Radu, Jan Maarten van Dijl, Kristina Haslinger

― 6 min read


Fungus Fights Back Fungus Fights Back resistant bacteria. A fungus could be key in battling
Table of Contents

In recent years, the world has faced a significant health crisis due to drug-resistant bacteria. These pesky microorganisms have become skilled at evading treatments that once worked against them. Scientists have pointed fingers at various culprits, but the truth is, bacteria are like the ultimate escape artists. As a result, the hunt for new medicines has never been more urgent. One promising avenue of research involves plants and fungi, which have been shown to produce a range of beneficial compounds.

The Marvels of Nature: A Fungal Alliance

Among the many players in this scene is a special endophytic fungus called Cosmosporella sp. VM-42, found lurking within the leaves of a medicinal plant known as Vinca minor. Endophytic fungi, like this one, live inside plants without causing harm, and they are known to produce a variety of Bioactive Compounds. Think of them as nature's little chemists, brewing up all sorts of interesting substances that might just help humanity in its fight against sickness.

Why Vinca Minor?

Vinca minor, also known as the lesser periwinkle, is not just your average green plant; it belongs to a family called Apocynaceae. This plant produces vinca alkaloids, compounds that have made their mark in traditional medicine. While Vinca minor has been used to aid in various health issues, its endophytic friends, like Cosmosporella sp. VM-42, have been largely ignored until now. It's time to shine a light on these unassuming fungi.

Getting to Know Cosmosporella sp. VM-42

To understand what makes Cosmosporella sp. VM-42 special, let's start with how researchers got their hands on it. Leaves from Vinca minor were collected, treated to get rid of unwanted microbes, and then placed on growth media where the fungus could thrive. After some time, researchers noticed this particular fungus could inhibit the growth of certain bacteria.

That’s right—this fungus has demonstrated the ability to kick some bacterial butt!

Identifying the Fungal Superstar

Once researchers suspected they had found a winner, the next step was to dive deeper into its identity. Morphological analyses were conducted, where the fungus was grown on various media. This included observing the color and size of the fungal colonies, as well as using microscopes to take a closer look at its structure.

After careful investigation, the fungus was identified as Cosmosporella sp. VM-42. It turns out that it belongs to a big family of fungi known for their diverse and complex lives.

A Treasure Trove of Bioactive Compounds

The most exciting aspect of Cosmosporella sp. VM-42 is its potential to produce various compounds that could be useful in medicine. When researchers analyzed its genetic material, they found 35 clusters of genes that could be responsible for producing these valuable bioactive substances. These gene clusters are like blueprints for making everything from antibiotics to cancer-fighting agents.

Antibacterial Tests: The Showdown

To see just how effective Cosmosporella sp. VM-42 could be, researchers conducted tests against multiple strains of bacteria, including both drug-sensitive and drug-resistant strains of Staphylococcus aureus (that's a fancy way to say some tough bacteria). The results? The extracts from this fungus showed significant antibacterial activity.

In simple terms, it was like watching a superhero take down villains left and right. The extracts were found to inhibit the growth of these bacteria, making it a promising candidate for further studies.

The Extraction Process: Creating the Potion

Harnessing the power of the fungus involved a multi-step extraction process. Researchers first grew the fungus in liquid culture. Once it had blossomed, they extracted the bioactive compounds using a cocktail of solvents. Think of it like brewing a magical potion, where each ingredient is essential for drawing out the desired benefits.

Diving Deeper: Metabolomics

But wait, there’s more! The researchers wanted to take a closer look at the compounds produced by Cosmosporella sp. VM-42. They performed metabolomic analyses, which essentially means they studied the small molecules produced by the fungus in great detail. By using advanced techniques, the team was able to identify around 26 different compounds, some of which had never been seen before.

These compounds included cyclodepsipeptides, ustilaginoidins, and lasiodiplodins. That’s quite the mouthful, but it’s all good stuff when it comes to medicinal potential.

Compound 27: The Belle of the Ball

Out of all the compounds produced, one stood out among the rest—compund 27. This particular compound, known as nectriapyrone, was isolated and identified. With a name like that, you can bet it has some drama behind it. Nectriapyrone has been associated with various biological activities, adding to the excitement about Cosmosporella sp. VM-42.

Testing the Waters: Antibacterial Action of Compound 27

To see if compound 27 could hold its own in the antibacterial arena, researchers conducted further tests. They evaluated its effectiveness against both methicillin-sensitive and methicillin-resistant Staphylococcus aureus strains. The results showed that compound 27 could significantly inhibit the growth of these bacteria, proving it is indeed a contender in the fight against drug-resistant infections.

The Genetic Blueprint: Whole Genome Sequencing

To unravel the secrets of Cosmosporella sp. VM-42, researchers turned to whole-genome sequencing. This high-tech method allowed them to read the genetic code of the fungus, shedding light on its many abilities. With a well-assembled genome, researchers identified genes that could lead to the production of even more beneficial compounds.

A Future Full of Potential

With all this valuable information, the researchers believe Cosmosporella sp. VM-42 holds great potential for developing new drugs. The encouraging results from both antibacterial tests and metabolomic analyses point to a promising future where this underappreciated fungus could become a heavyweight champion in the fight against bacterial infections.

Conclusion: Nature’s Hidden Treasures

In summary, Cosmosporella sp. VM-42 is more than just a fungus; it is a beacon of hope in the quest for new antibacterial agents. As humans continue to battle drug-resistant bacteria, looking to nature for solutions is a smart strategy. Fungi like Cosmosporella sp. VM-42 represent untapped resources that could lead to groundbreaking discoveries in the pharmaceutical world.

So, who knew that a little fungus from a common plant could be such a formidable opponent? Nature never ceases to amaze us with its hidden treasures. As we continue our exploration of endophytic fungi and their capabilities, we may just find the next superhero in our battle against illness.

The Bottom Line

The story of Cosmosporella sp. VM-42 serves as a reminder of the importance of biodiversity and the potential benefits that nature has to offer. As researchers continue their work, we can only hope that this and other fungi will open new doors to medical advancements. After all, it turns out that beneath our feet and among the leaves, there may be countless unsung heroes waiting for their chance to shine.

And who knows, one day you might just find a fungi superhero in your backyard!

Original Source

Title: The endophytic fungus Cosmosporella sp. VM-42 from Vinca minor is a source of bioactive compounds with potent activity against drug-resistant bacteria

Abstract: Medicinal plants serve as valuable resources for the isolation of endophytic fungi. Vinca minor is a well-known producer of important vinca alkaloids and emerges as a promising source of endophytic fungi with antibacterial potential and biosynthetic capacity. In this study, we isolated an endophytic fungus from V. minor and identified it as Cosmosporella sp. VM-42. To date, relatively little is known about this fungal genus. The ethyl acetate extract of this isolate selectively inhibited Gram-positive bacteria, such as methicillin-sensitive and methicillin-resistant Staphylococcus aureus (MSSA and MRSA). Therefore, we isolated the most abundant compound from the crude extract and identified it as nectriapyrone with MIC and MBC values ranging from 125 to 62.5 {micro}g/mL against MSSA and MRSA strains. We further sequenced and annotated the 39.07 Mb genome of the isolate, revealing that it encodes 9,842 protein-coding genes, including 415 genes for carbohydrate-active enzymes and various biosynthetic gene clusters. Our untargeted metabolomic analysis shows that the fungus produces various secondary metabolites, including cyclodepsipeptides, dimeric naphtho-{gamma}-pyrones, and macrolactones, which are known to have antifungal and antibacterial activities. In addition, we used small-molecule epigenetic modulators to activate the expression of silent biosynthetic gene clusters to broaden the chemical profile of Cosmosporella sp. VM-42. Taken together, we provide a first systematic analysis of Cosmosporella sp. VM-42, and our results show that it is a promising source of compounds with pharmacological potential against drug resistant bacteria. HighlightsO_LIFirst comprehensive study of Cosmosporella sp. VM-42 by genomics and metabolomics C_LIO_LIThe fungus produces chemically-diverse secondary metabolites with antibacterial activity C_LIO_LINectriapyrone, the main compound, shows bactericidal activity against MSSA and MRSA C_LIO_LISmall-molecule epigenetic modulators trigger production of putatively new secondary metabolites. C_LIO_LIOther secondary metabolites of Cosmosporella may present novel bioactivities. C_LI

Authors: Ting He, Xiao Li, Rosario del Carmen Flores-Vallejo, Ana-Maria Radu, Jan Maarten van Dijl, Kristina Haslinger

Last Update: 2024-12-27 00:00:00

Language: English

Source URL: https://www.biorxiv.org/content/10.1101/2024.12.27.630490

Source PDF: https://www.biorxiv.org/content/10.1101/2024.12.27.630490.full.pdf

Licence: https://creativecommons.org/licenses/by/4.0/

Changes: This summary was created with assistance from AI and may have inaccuracies. For accurate information, please refer to the original source documents linked here.

Thank you to biorxiv for use of its open access interoperability.

More from authors

Similar Articles